secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oaktree Acquisition Corp. III Life Sciences (OACC)
CIK:        0002029769
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242643
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as independent director
--------------------------------------------------------------------------------

- Appointed Oct 17, 2025 as Class II director on audit, nominating, and compensation committees; deemed independent under Nasdaq and Rule 10A-3.
- Co-founder & Managing Partner of Averin Capital (since May 2025); former Partner/GP at Flagship Pioneering (2005-2025); founder/CEO of Valo Health.
- No cash compensation; eligible to invest non-controlling minority interest in Oaktree Acquisition Holdings III LS, consistent with other independent directors.
- Will execute standard Letter Agreement and Indemnity Agreement on same terms as directors/officers from IPO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2029769/000119312525242643/0001193125-25-242643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2029769/000119312525242643/d41718d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer